Pulmonx
Martin Schneider has over 30 years of work experience in finance and operations. Martin started their career at Abbott AG as a Finance Administrator/Controller for the Diagnostic Division. Martin then worked at Metro International Management AG as an International Controller before moving on to Alcon Pharmaceuticals Ltd. where they held various roles including Area Controller, EURMEA Controller, and Director of Finance and Operations. Martin also worked at Alcon Laboratories, Inc. as a Controller for Export Markets, EURMEA. In 2008, they joined Alcon Laboratories, Inc. as the Director of Finance and Operations for EURMEA SSC, and later transitioned to Pulmonx as the VP Finance, CFO International. Throughout their career, Martin has held positions of increasing responsibility and has demonstrated expertise in financial management and strategy.
Martin Schneider obtained a Bachelor's degree in Finance and Accounting from the University of Applied Sciences Bern between 1984 and 1987. Prior to that, they acquired a Federal Vocational Education and Training Diploma in Accounting from the Business Administration School Biel, although the specific duration of this program is unknown.
This person is not in any teams
This person is not in any offices
Pulmonx
2 followers
Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1